trial · primary record
Momelotinib
Primary Myelofibrosis
| Phase | Phase 2 |
|---|---|
| Status | ACTIVE |
| Sponsor | Unknown |
| Enrolment | 237 |
| Primary completion | 2028-12-29 |
| Primary endpoint | Number of Participants with treatment emergent adverse events (TEAEs) and serious adverse events (SAEs) by severity |
| Registry ID | NCT03441113 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T02:32:48.592Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT03441113
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.